Alkem Lab

Who are the top shareholders of the Alkem Lab?

The top shareholders of Alkem Lab include promoters, with Sarandhar Singh holding 19.42%, mutual funds at 14.97%, foreign institutional investors at 9.41%, and individual investors with a combined 15.77%. The largest public shareholder is the ICICI Prudential Multi-Asset Fund, holding 4.11%.

The top shareholders of Alkem Lab include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Sarandhar Singh holding the highest individual stake at 19.42%. Mutual funds collectively hold 14.97% of the shares through 27 different schemes, while FIIs account for 9.41% with 473 different investors. The highest public shareholder is the ICICI Prudential Multi-Asset Fund, which holds 4.11%. Additionally, individual investors have a combined holding of 15.77%.

how big is Alkem Lab?

As of Jun 06, Alkem Laboratories Ltd has a market capitalization of 58,204.24 Cr, with recent net sales of 12,756.59 Cr and net profit of 2,153.18 Cr over the last four quarters.

Market Cap: Alkem Laboratories Ltd has a market capitalization of 58,204.24 Cr and is classified as a Large Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Dec'24, Sep'24, Jun'24, and Mar'24, is 12,756.59 Cr. The sum of Net Profit for the same period is 2,153.18 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 10,312.06 Cr, while the Total Assets amount to 14,060.07 Cr.

Has Alkem Lab declared dividend?

Yes, Alkem Laboratories Ltd has declared a dividend of 1850% (₹37 per share), with an ex-date of February 14, 2025. The company has shown varying total returns over different periods, with a notable 110.91% total return over the last 5 years.

Alkem Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1850%<BR>- Amount per share: 37<BR>- Ex-date: 14 Feb 25<BR><BR>Dividend Yield: 0.87%.<BR><BR>Total Returns by Period:<BR>Over the last 6 months, the price return was -11.76%, the dividend return was 0.67%, resulting in a total return of -11.09%.<BR><BR>In the 1-year period, the price return was 1.02%, the dividend return was 0.83%, leading to a total return of 1.85%.<BR><BR>For the 2-year period, the price return was 43.8%, the dividend return was 2.56%, which resulted in a total return of 46.36%.<BR><BR>During the 3-year period, the price return was 56.49%, the dividend return was 3.90%, culminating in a total return of 60.39%.<BR><BR>In the 4-year period, the price return was 53.99%, the dividend return was 4.83%, yielding a total return of 58.82%.<BR><BR>Over the last 5 years, the price return was 103.29%, the dividend return was 7.62%, resulting in a total return of 110.91%.<BR><BR>Overall, Alkem Laboratories Ltd has declared a significant dividend, which reflects positively on the company's commitment to returning value to shareholders. The total returns over various periods show a mix of performance, with particularly strong returns over the longer term.

Who are the peers of the Alkem Lab?

Alkem Lab's peers include Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Glenmark Pharma, Glaxosmi. Pharma, Biocon, Laurus Labs, Cohance Life, and Ipca Labs. In terms of management risk, growth, and capital structure, they vary from excellent to average, with Laurus Labs showing the highest 1-year return at 76.44% and Zydus Lifesci. the lowest at -18.37%.

Peers: The peers of Alkem Lab are Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Glenmark Pharma, Glaxosmi. Pharma, Biocon, Laurus Labs, Cohance Life, and Ipca Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India and Glaxosmi. Pharma, while Good management risk is found at Zydus Lifesci., Aurobindo Pharma, Laurus Labs, Alkem Lab, and Cohance Life, and Average management risk is noted at Lupin, Glenmark Pharma, and Biocon. In terms of Growth, Excellent growth is seen at Zydus Lifesci. and Lupin, while Average growth is noted at Laurus Labs and Biocon, and Below Average growth is observed at Aurobindo Pharma, Glenmark Pharma, Alkem Lab, Glaxosmi. Pharma, and Cohance Life. For Capital Structure, Excellent capital structure is found at Zydus Lifesci., Abbott India, Aurobindo Pharma, Alkem Lab, Glaxosmi. Pharma, Cohance Life, and Ipca Labs, while Good capital structure is noted at Lupin and Glenmark Pharma, and Average capital structure is seen at Laurus Labs and Biocon.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Laurus Labs at 76.44%, while the peer with the lowest is Zydus Lifesci. at -18.37%. Alkem Lab's 1-year return is -5.54%, which is higher than Zydus Lifesci. but lower than Laurus Labs. Additionally, the peers with negative six-month returns include Zydus Lifesci., Aurobindo Pharma, and Glenmark Pharma.

Who are in the management team of Alkem Lab?

As of March 2023, the management team of Alkem Lab includes Basudeo N Singh (Executive Chairman), Sandeep Singh (Managing Director), and several Executive and Non-Executive Directors, along with the Company Secretary, Manish Narang, who collectively guide the company's governance and strategy.

As of March 2023, the management team of Alkem Lab includes the following individuals:<BR><BR>1. Basudeo N Singh - Executive Chairman<BR>2. Sandeep Singh - Managing Director<BR>3. Mritunjay Kumar Singh - Executive Director<BR>4. Sarvesh Singh - Executive Director<BR>5. Madhurima Singh - Executive Director<BR>6. Srinivas Singh - Executive Director<BR>7. A K Purwar - Non-Executive & Independent Director<BR>8. Sangeeta Kapiljit Singh - Non-Executive & Independent Director<BR>9. Sudha Ravi - Non-Executive & Independent Director<BR>10. Dheeraj Sharma - Non-Executive & Independent Director<BR>11. Narendra Aneja - Non-Executive & Independent Director<BR>12. Sujjain Talwar - Independent Director<BR>13. Manish Narang - Company Secretary & Compliance Officer<BR><BR>This diverse team plays a crucial role in the governance and strategic direction of the company.

What does Alkem Lab do?

Alkem Laboratories Ltd is a prominent Indian pharmaceutical company founded in 1973, specializing in the development and sale of pharmaceutical and nutraceutical products. As of March 2025, it reported net sales of ₹31,438 Cr and a net profit of ₹3,059 Cr, with a market capitalization of ₹59,352 Cr.

Overview:<BR>Alkem Laboratories Ltd is a leading Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Large Cap company.<BR><BR>History:<BR>Alkem Laboratories Ltd was incorporated in the year 1973. The latest quarterly results reported are for March 2025, showcasing the company's ongoing operations in the pharmaceutical sector.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 31,438 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3,059 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 59,352 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.85% <BR>Debt-Equity: -0.09 <BR>Return on Equity: 18.07% <BR>Price to Book: 4.92 <BR><BR>Contact Details:<BR>Address: Alkem House Senapati Bapat Marg, Lower Parel Mumbai Maharashtra : 400013 <BR>Tel: 91-22-39829999 <BR>Email: investors@alkem.com <BR>Website: http://www.alkemlabs.com

When is the next results date for Alkem Lab?

Alkem Lab will announce its results on 12 August 2025.

Alkem Lab will declare its results on 12 August 2025.

Is Alkem Lab overvalued or undervalued?

As of November 13, 2025, Alkem Lab is fairly valued with a PE ratio of 30.06 and solid financial metrics, despite recent stock performance lagging behind the Sensex.

As of 13 November 2025, the valuation grade for Alkem Lab has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 30.06, a Price to Book Value of 5.70, and an EV to EBITDA ratio of 25.45. In comparison to its peers, Sun Pharma has a higher PE ratio of 36.15 and an EV to EBITDA of 23.85, while Cipla is more attractively valued with a PE of 22.65 and an EV to EBITDA of 16.03.<BR><BR>Alkem Lab's financial metrics indicate a solid performance, with a ROCE of 19.77% and a ROE of 18.07%. Despite recent stock performance lagging behind the Sensex over one year (2.53% vs. 8.74%), the company's strong ratios suggest it is positioned well within the pharmaceuticals sector. Overall, Alkem Lab appears to be fairly valued in the current market context.

How has been the historical performance of Alkem Lab?

Alkem Lab has shown consistent growth in net sales and profits, with net sales increasing from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025, and profit after tax rising from 1,149.31 Cr to 2,216.00 Cr during the same period, indicating strong financial performance.

Answer:<BR>The historical performance of Alkem Lab shows a consistent growth trend in net sales and profits over the years, culminating in significant figures for the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Alkem Lab's net sales increased from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025. The company's operating profit (PBDIT) also saw growth, reaching 3,005.89 Cr in March 2025, up from 1,577.61 Cr in March 2020. Profit before tax increased from 1,259.79 Cr in March 2020 to 2,527.03 Cr in March 2025, while profit after tax rose from 1,149.31 Cr to 2,216.00 Cr over the same period. The earnings per share (EPS) improved significantly from 94.28 in March 2020 to 181.14 in March 2025. On the balance sheet, total assets grew from 9,012.97 Cr in March 2020 to 15,952.85 Cr in March 2025, and total liabilities increased from 9,012.97 Cr to 15,952.85 Cr during the same timeframe. Cash flow from operating activities also showed an upward trend, reaching 1,912.00 Cr in March 2025, although the net cash outflow was recorded at -186.00 Cr. Overall, Alkem Lab has demonstrated robust growth in sales, profits, and assets over the years, indicating a strong financial performance.

Is Alkem Lab technically bullish or bearish?

As of December 1, 2025, Alkem Lab's technical trend is mildly bullish, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Alkem Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with no clear monthly trend. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some bearish signals in the monthly indicators.

Are Alkem Laboratories Ltd latest results good or bad?

Alkem Laboratories Ltd's latest results are mixed; while net sales grew 10.74% year-over-year, there was a 6.60% sequential decline, and net profit fell 16.87% from the previous quarter, raising concerns about sustainability and impacting investor sentiment.

Alkem Laboratories Ltd's latest results present a mixed picture. For Q3 FY26, the company reported net sales of ₹3,736.82 crores, which reflects a solid year-over-year growth of 10.74%. However, this represents a sequential decline of 6.60% from the previous quarter, indicating some challenges in maintaining momentum.<BR><BR>The net profit for the quarter was ₹636.02 crores, showing a slight year-over-year increase of 1.63%, but it experienced a significant sequential drop of 16.87%. This decline in profit, coupled with margin pressures—operating margin decreased to 22.16% and PAT margin fell to 17.49%—suggests that the company is facing operational headwinds, particularly from rising costs and competitive pricing dynamics.<BR><BR>While the nine-month performance for FY26 shows stronger overall growth with a 12.96% increase in net sales and a 10.73% rise in net profit compared to the same period last year, the recent quarterly results raise concerns about the sustainability of this growth. The market has reacted negatively, with the stock underperforming against benchmarks following the announcement.<BR><BR>In summary, while Alkem Laboratories has demonstrated resilience and growth over the longer term, the latest quarterly results indicate some challenges that could affect investor sentiment and future performance.

Should I buy, sell or hold Alkem Laboratories Ltd?

Why is Alkem Laboratories Ltd falling/rising?

As of 16-Mar, Alkem Laboratories Ltd's stock price is at 5,298.55, down 0.99% and on a downward trend for four consecutive days, totaling a 5.7% decline. The stock is underperforming against the Sensex and shows signs of liquidity issues, contributing to negative investor sentiment.

As of 16-Mar, Alkem Laboratories Ltd's stock price is falling, currently at 5,298.55, reflecting a decrease of 52.95 (-0.99%). The stock has been on a downward trend, having lost value for the last four consecutive days, resulting in a total decline of 5.7% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In the context of broader market performance, Alkem's stock has underperformed relative to the Sensex over the past week and month, with declines of 2.96% and 3.32%, respectively. Although the stock has shown positive returns over the past year (+13.05%) and in the long term (+68.07% over three years), recent performance suggests a struggle to maintain momentum.<BR><BR>Factors contributing to the stock's decline include poor long-term growth, as evidenced by an operating profit growth rate of only 8.21% over the last five years. Furthermore, the company's financial health indicators, such as the lowest cash and cash equivalents at Rs 1,547.65 crore and a low debtors turnover ratio of 4.49 times, suggest potential liquidity issues. Despite high management efficiency and institutional holdings, these negative factors appear to be influencing investor sentiment, leading to the current decline in stock price.

Which are the latest news on Alkem Lab?